{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for clindamycin root_relationships_relatedSubstance_refPname in Related Substance Name (approximate match)
AMPROTROPINE (Syntropan) is the phosphate salt of
3 diethylamine, 2.2 dimethylpropanol
tropic acid ester. Syntropan is antispasmodic. Its main effect is parasympathetic, and its internal uses are
chiefly the same as those of atropine. Syntropan produces relaxation of the tone of the stomach and inhibition of peristaltic activity. The effect of syntropan on gastric secretion excited by a meat extract meal and histamine is weak as compared with atropine. Its
advantages as a mydriatic were also described: the rapid effect; the short duration; no general dangers nor discomforts; no local dangers, as damaging the corneal epithelium, or increasing the intraocular
pressure; no delay in returning to work for the patient.
Status:
Other
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Sphingosine harbors two chiral centers and therefore exhibits four stereoisomers, only one of which, the D-erythro (2S,3R) is known to exist naturally. ERYTHRO-SPHINGOSINE, (±)- is a mixture of two isomers: inactive ERYTHRO-SPHINGOSINE, (+)- and the active ERYTHRO-SPHINGOSINE, (-), also known as D-erythro (2S,3R)-SPHINGOSINE or D-erythro –SPHINGOSINE. It was found, that D-erythro –SPHINGOSINE acts as a potent inhibitor of protein kinase C and of transient receptor potential melastatin 7 (TRPM7). Besides, was shown, that sphingosine may be efficacious against alveolar rhabdomyosarcoma, irrespective of TP53 mutation status. It also could evolve as alternative treatment options for aggressive lymphomas via PKC inhibition, apoptosis, and autophagy.